Delivery Order SPE2DB25D3108-SPE2DB25FPDLU
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,700.12 on July 28, 2025, for the supply of Mounjaro 12.5 mg/0.5 ml pen injections. This firm fixed price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 29, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,360.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on July 25, 2025, with a completion date of July 28, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the Department of Defense medical supply chain. The work will be performed at the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,082.99 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pen injectors on July 24, 2025. This firm fixed-price delivery order, which is a child contract under a larger indefinite delivery vehicle, represents a routine pharmaceutical procurement for military healthcare needs. The contract was competitively awarded without set-aside designation and specifies performance at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,586.22 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL). This firm fixed-price delivery order is non-competitive and utilizes a competitively awarded indefinite delivery contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. As a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,408.25 on July 28, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors. This non-competitive delivery order, with a completion date of July 29, 2025, will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract utilizes firm fixed pricing and represents a child order under a larger contract vehicle supporting federal medical procurement needs. This delivery...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $3,265.71 by the Defense Logistics Agency (DLA) for the supply of Mounjaro 5 mg/0.5 ml pen injectors. This firm fixed-price delivery order, awarded on July 31, 2025, with completion targeted for August 1, 2025, represents a small-value pharmaceutical transaction under the company's broader contracting relationship with DLA. The contract involves no set-aside designation, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,182.67 on August 8, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injectors with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $1,360.45 delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order fulfilling pharmaceutical supply needs for federal medical procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $10,431.03 delivery order on July 25, 2025, for Mounjaro 12.5 mg/0.5 ml pen injectors, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,431.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injectables on July 24, 2025, with an ultimate completion date of July 25, 2025. This contract represents a non-set-aside competitive award for pharmaceutical supply to federal healthcare systems. The award was performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters and a major hub for...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDLUDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,720.90 on July 28, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's extensive contract portfolio with the Defense Logistics Agency demonstrates its capability to deliver specialty pharmaceuticals, including diabetes and neurological medications, across multiple therapeutic domains. This particular delivery order represents routine pharmaceutical procurement through DLA's established medical supply chain to support federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 7/28/25 |